222 related articles for article (PubMed ID: 15797981)
21. COX-2-specific inhibitors and the kidney: effect on hypertension and oedema.
Whelton A
J Hypertens Suppl; 2002 Sep; 20(6):S31-5. PubMed ID: 12683425
[TBL] [Abstract][Full Text] [Related]
22. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C
Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336
[TBL] [Abstract][Full Text] [Related]
23. Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib?
Rahme E; Hunsche E; Toubouti Y; Chabot I
Arthritis Rheum; 2006 Feb; 55(1):27-34. PubMed ID: 16463408
[TBL] [Abstract][Full Text] [Related]
24. Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients.
Whelton A; Fort JG; Puma JA; Normandin D; Bello AE; Verburg KM;
Am J Ther; 2001; 8(2):85-95. PubMed ID: 11304662
[TBL] [Abstract][Full Text] [Related]
25. Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials.
Goldstein JL; Bello AE; Spalding W; Suh S; Fort JG
J Rheumatol; 2005 Jan; 32(1):111-7. PubMed ID: 15630735
[TBL] [Abstract][Full Text] [Related]
26. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial.
Gibofsky A; Williams GW; McKenna F; Fort JG
Arthritis Rheum; 2003 Nov; 48(11):3102-11. PubMed ID: 14613272
[TBL] [Abstract][Full Text] [Related]
27. The effects of rofecoxib on 24-h ambulatory blood pressure and heart rate monitoring in patients with hypertension and osteoarthritis.
Derici U; Goker B; Ayerden-Ebinc F; Altok KR; Erten Y; Haznedaroglu S; Aydin M; Arinsoy T; Sindel S
Int J Tissue React; 2005; 27(2):69-73. PubMed ID: 16035651
[TBL] [Abstract][Full Text] [Related]
28. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.
Solomon SD; Pfeffer MA; McMurray JJ; Fowler R; Finn P; Levin B; Eagle C; Hawk E; Lechuga M; Zauber AG; Bertagnolli MM; Arber N; Wittes J;
Circulation; 2006 Sep; 114(10):1028-35. PubMed ID: 16943394
[TBL] [Abstract][Full Text] [Related]
29. A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population.
Becker RV; Burke TA; McCoy MA; Trotter JP
Clin Ther; 2003 Feb; 25(2):647-62. PubMed ID: 12749519
[TBL] [Abstract][Full Text] [Related]
30. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure.
Aw TJ; Haas SJ; Liew D; Krum H
Arch Intern Med; 2005 Mar; 165(5):490-6. PubMed ID: 15710786
[TBL] [Abstract][Full Text] [Related]
31. Clinical profiles of celecoxib and rofecoxib in the rheumatic diseases.
Gibofsky A
J Hypertens Suppl; 2002 Sep; 20(6):S25-30. PubMed ID: 12683424
[TBL] [Abstract][Full Text] [Related]
32. Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs.
Zembowicz A; Mastalerz L; Setkowicz M; Radziszewski W; Szczeklik A
Arch Dermatol; 2003 Dec; 139(12):1577-82. PubMed ID: 14676074
[TBL] [Abstract][Full Text] [Related]
33. A retrospective review of the effect of COX-2 inhibitors on blood pressure change.
Cho J; Cooke CE; Proveaux W
Am J Ther; 2003; 10(5):311-7. PubMed ID: 12975714
[TBL] [Abstract][Full Text] [Related]
34. Comparison of changes in blood pressure measurements and antihypertensive therapy in older, hypertensive, ambulatory care patients prescribed celecoxib or rofecoxib.
Nietert PJ; Ornstein SM; Dickerson LM; Rothenberg RJ
Pharmacotherapy; 2003 Nov; 23(11):1416-23. PubMed ID: 14620388
[TBL] [Abstract][Full Text] [Related]
35. COX-2-specific inhibitors: prescribing patterns in a large managed care health system and strategies to minimize costs.
Weideman RA; Kelly KC; Kelley CL; Cryer B
Am J Manag Care; 2002 Oct; 8(10):869-77. PubMed ID: 12395955
[TBL] [Abstract][Full Text] [Related]
36. Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada.
Rahme E; Toubouti Y; Hunsche E
Rheumatology (Oxford); 2006 Jul; 45(7):903-10. PubMed ID: 16461440
[TBL] [Abstract][Full Text] [Related]
37. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.
Johnsen SP; Larsson H; Tarone RE; McLaughlin JK; Nørgård B; Friis S; Sørensen HT
Arch Intern Med; 2005 May; 165(9):978-84. PubMed ID: 15883235
[TBL] [Abstract][Full Text] [Related]
38. Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study.
Depont F; Fourrier A; Merlière Y; Droz C; Amouretti M; Bégaud B; Bénichou J; Moride Y; Velo GP; Sturkenboom M; Blin P; Moore N;
Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):891-900. PubMed ID: 17351983
[TBL] [Abstract][Full Text] [Related]
39. Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: a class effect?
Hudson M; Rahme E; Richard H; Pilote L
Arthritis Rheum; 2007 Apr; 57(3):516-23. PubMed ID: 17394181
[TBL] [Abstract][Full Text] [Related]
40. [Cyclooxygenase-2 inhibitors in postoperative pain management].
Güneş Y; Işik G
Agri; 2004 Jul; 16(3):7-16. PubMed ID: 15382000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]